Ignyte Bio is delighted to celebrate the Nobel Prize in Medicine awarded for the discovery of regulatory T cells (Tregs) and the Fox P3 protein. This year’s recognition is especially significant for the Seattle scientific community, as two of the three laureates—Dr. Mary E. Brunkow and Dr. Fred Ramsdell—hail from Seattle, Washington, which is also home to Ignyte Bio. Their collaborative work with Dr. Shimon Sakaguchi has played a pivotal role in enhancing our understanding of autoimmune diseases and immune tolerance.
Researchers focused on autoimmune diseases and immune tolerance have long valued the critical role of Tregs in disease mechanisms. With the Nobel Prize spotlighting their importance, the impact of Tregs is now widely recognized across the global scientific community.
Induced Tregs are ideal for running Treg suppression assays to help you understand if your drug candidate is able to successfully suppress or inhibit the immune response. If you need help with assay development, chat with one of our scientists today.
For those seeking to utilize the latest advancements in immunology, Ignyte Bio offers ready-to-use induced Tregs. Ignyte Bio generates induced Tregs in culture from CD4+ T cells. These induced Tregs can inhibit T cell proliferation as shown in Fig.1. Large batches of induced Tregs offer cost-effective applications in your immunology or oncology research projects.
These cells are cost-effective and characterized by the markers CD25+, CD127 low/-, and Fox P3+. Each product comes with a comprehensive Certificate of Analysis that includes detailed donor demographics, HLA type, product morphology, and T Reg suppression assay data.
Fig.1
Fig.2 Induced Tregs Phenotype
For induced Tregs and other unique antigen specific T cells, visit us at: https://www.ignytebio.com/product-category/cells/